The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early warning signs monitoring by service users with schizophrenia has shown promise in preventing relapse but the quality of evidence is low. We aimed to establish the feasibility of undertaking a definitive randomised controlled trial to determine the effectiveness of a blended digital intervention for relapse prevention in schizophrenia. METHODS: This multicentre, feasibility, cluster randomised controlled trial aimed to compare Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery (EMPOWER) with treatment as usual in community mental health services (CMHS) in Glasgow and Melbourne. CMHS were the unit of randomisation, selected on the basis of those that probably had five or more care coordinators willing to participate. Participants were eligible if they were older than 16 years, had a schizophrenia or related diagnosis confirmed via case records, were able to provide informed consent, had contact with CMHS, and had had a relapse within the previous 2 years. Participants were randomised within stratified clusters to EMPOWER or to continue their usual approach to care. EMPOWER blended a smartphone for active monitoring of early warning signs with peer support to promote self-management and clinical triage to promote access to relapse prevention. Main outcomes were feasibility, acceptability, usability, and safety, which was assessed through face-to-face interviews. App usage was assessed via the smartphone and self-report. Primary end point was 12 months. Participants, research assistants and other team members involved in delivering the intervention were not masked to treatment conditions. Assessment of relapse was done by an independent adjudication panel masked to randomisation group. The study is registered at ISRCTN (99559262). FINDINGS: We identified and randomised eight CMHS (six in Glasgow and two in Melbourne) comprising 47 care coordinators. We recruited 86 service users between Jan 19 and Aug 8, 2018; 73 were randomised (42 [58%] to EMPOWER and 31 [42%] to treatment as usual). There were 37 (51%) men and 36 (49%) women. At 12 months, main outcomes were collected for 32 (76%) of service users in the EMPOWER group and 30 (97%) of service users in the treatment as usual group. Of those randomised to EMPOWER, 30 (71%) met our a priori criterion of more than 33% adherence to daily monitoring that assumed feasibility. Median time to discontinuation of these participants was 31·5 weeks (SD 14·5). There were 29 adverse events in the EMPOWER group and 25 adverse events in the treatment as usual group. There were 13 app-related adverse events, affecting 11 people, one of which was serious. Fear of relapse was lower in the EMPOWER group than in the treatment as usual group at 12 months (mean difference -7·53 (95% CI -14·45 to 0·60; Cohen's d -0·53). INTERPRETATION: A trial of digital technology to monitor early warning signs blended with peer support and clinical triage to detect and prevent relapse appears to be feasible, safe, and acceptable. A further main trial is merited. FUNDING: UK National Institute for Health Research Health Technology Assessment programme and the Australian National Health and Medical Research Council.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skivington, K., Matthews, L., Simpson, S. A., Craig, P., Baird, J., Blazeby, J. M., Boyd, K. A., Craig, N., French, D. P., McIntosh, E., et al. (2021) · BMJ · doi:10.1136/bmj.n2061 · Cited by 5,808
Consort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510 · cited 1×
“The study was planned and implemented in concordance with the Consolidated Standards of Reporting Trials (CONSORT) cluster trial extension, 13 and we separately published a study protocol.”
MethodCharlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby058 · Cited by 1,647
Mohr, D. C., Cuijpers, P., & Lehman, K. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.1602 · Cited by 1,097 · cited 1×
“11 Therefore, in the context of recurring psychosis and lingering fear of relapse, digital interventions, blended with peer support to promote self-management and clinical triage enabling timely human support and shared decision making, offer an important opportunity for relapse prevention.”
BackgroundDevelopment and validation of the user version of the Mobile application rating scale (uMARS)
Stoyanov, S. R., Hides, L., Kavanagh, D. J., & Wilson, H. (2016) · JMIR mhealth and uhealth · doi:10.2196/mhealth.5849 · Cited by 872
Teare, M. D., Dimairo, M., Shephard, N., Hayman, A., Whitehead, A., & Walters, S. J. (2014) · Trials · doi:10.1186/1745-6215-15-264 · Cited by 773
Alvarez-Jimenez, M., Priede, A., Hetrick, S. E., Bendall, S., Killackey, E., Parker, A. G., McGorry, P. D., & Gleeson, J. F. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.05.007 · Cited by 511
Self-citationFeasibility, Acceptability, and Preliminary Efficacy of a Smartphone Intervention for Schizophrenia
Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., & Mueser, K. T. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu033 · Cited by 493
Birchwood, M., Smith, J., Macmillan, F., Hogg, B., Prasad, R., Harvey, C., & Bering, S. (1989) · Psychological Medicine · doi:10.1017/s0033291700024247 · Cited by 334
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Cited by
Torous, J., Linardon, J., Goldberg, S. B., Sun, S., Bell, I., Nicholas, J., Hassan, L., Hua, Y., Milton, A., & Firth, J. (2025) · World Psychiatry · doi:10.1002/wps.21299 · Cited by 323
Cohen, A., Naslund, J. A., Chang, S., Nagendra, S., Bhan, A., Rozatkar, A., Thirthalli, J., Bondre, A., Tugnawat, D., Reddy, P. V., et al. (2023) · Schizophrenia · doi:10.1038/s41537-023-00332-5 · Cited by 90
Systematic review and meta-analysis of adverse events in clinical trials of mental health apps
Linardon, J., Fuller-Tyszkiewicz, M., Firth, J., Goldberg, S. B., Anderson, C., McClure, Z., & Torous, J. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01388-y · Cited by 44
Arnautovska, U., Ritchie, G., Soole, R., Menon, A., Korman, N., Milton, A., Varnfield, M., Kelly, J., Jansen, P., Baker, A., et al. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s513272 · Cited by 7
“23 Further, smartphone apps have also been used with people with SSD to target more complex outcomes, such as relapse prevention, 24 social functioning, 25 and psychosis symptoms.”
Metadata
- Authors
- Gumley, A. I., Bradstreet, S., Ainsworth, J., Allan, S., Alvarez-Jimenez, M., Aucott, L., Birchwood, M., Briggs, A., Bucci, S., Cotton, S. M., Engel, L., French, P., Lederman, R., Lewis, S., Machin, M., MacLennan, G., McLeod, H., McMeekin, N., Mihalopoulos, C., Morton, E., Norrie, J., Schwannauer, M., Singh, S. P., Sundram, S., Thompson, A., Williams, C., Yung, A. R., Farhall, J., & Gleeson, J.
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 9
- Issue
- 6
- Pages
- 477-486
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W4280573135
- Cited by
- 71
- References
- 14
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. https://app.cochat.ai/papers/10.1016/s2215-0366(22)00103-1
- The paper
- Gumley, A. I., Bradstreet, S., Ainsworth, J., Allan, S., Alvarez-Jimenez, M., Aucott, L., Birchwood, M., Briggs, A., Bucci, S., Cotton, S. M., Engel, L., French, P., Lederman, R., Lewis, S., Machin, M., MacLennan, G., McLeod, H., McMeekin, N., Mihalopoulos, C., . . . Gleeson, J. (2022). The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(22)00103-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.